AEON Biopharma, Inc. — Form 8-K Summary
Reporting date: May 23, 2023. The filing was submitted by Priveterra Acquisition Corp., a Delaware special purpose acquisition company, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits).
Business Context and Reporting Period
AEON Biopharma, Inc. published a final presentation for use in presentations to certain AEON stockholders and other persons. The presentation was furnished as Exhibit 99.1 in connection with the filing. The filing does not report a quarterly or annual financial period.
Financial Metrics and Liquidity
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
- No financial statements or financial results are included in the provided filing text.
Material Changes Versus Prior Period
The filing does not disclose financial or operating changes versus a prior comparable period. It reports only the furnishing of AEON’s final presentation.
Guidance, Outlook, Risks, and Unusual Items
- The text provided does not include the contents of Exhibit 99.1; therefore, any guidance, outlook, management commentary, risks, contingencies, transaction terms, or unusual items in the presentation cannot be assessed.
- The information under Item 7.01, including Exhibit 99.1, is furnished and is not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into Priveterra’s other filings, except as otherwise stated in the filing.
- The filing identifies Priveterra as an emerging growth company and indicates that its securities were listed on Nasdaq under the symbols PMGMU, PMGM, and PMGMW.
Investor Verification Items
- Review Exhibit 99.1 to verify AEON’s business description, transaction-related information, financial projections, funding assumptions, and risk disclosures.
- Confirm whether the presentation contains forecasts or other forward-looking statements and assess the assumptions supporting them.
- Verify the status and terms of the proposed transaction or business combination, if described in the presentation.
- Review subsequent SEC filings for updated financial information, transaction developments, financing requirements, and material risks.